Merus N.V. (MRUS)
| Previous close | 24.05 |
| Open | 23.83 |
| Bid | 23.31 x 800 |
| Ask | 23.36 x 1200 |
| Day's range | 23.24 - 24.30 |
| 52-week range | 13.47 - 33.09 |
| Volume | |
| Avg. volume | 368,337 |
| Market cap | 1.068B |
| Beta (5Y monthly) | 0.90 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Globe Newswire
Merus Announces Financial Results for the Second Quarter and Provides Business Update
- Clinical update of zenocutuzumab (Zeno) presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting - Zeno represents a potential new standard of care for NRG1+ cancer - Clinical update of MCLA-129 planned for second half of 2022; expansion cohorts including combination with osimertinib planned - Clinical update of petosemtamab (Peto) planned for first half of 2023 UTRECHT, The Netherlands and CAMBRIDGE, Mass., Aug. 08, 2022 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (
- Globe Newswire
Merus Presents Clinical Data on Zenocutuzumab (Zeno) in NRG1-fusion (NRG1+) Cancer at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting (Oral Abstract)
34% overall response rate in 79 evaluable patients with measurable disease9.1 months median duration of responseTumor reduction in 70% of patientsZeno observed to be very well-toleratedPotential new standard of care for patients with NRG1+ cancerInvestor call to discuss clinical results on Sunday, June 5 at 6:00 p.m. CT UTRECHT, The Netherlands and CAMBRIDGE, Mass., June 05, 2022 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, “the Company”, “we”, or “our”), a clinical-stage oncology com
- Globe Newswire
Merus to Participate in a Fireside Chat at the Jefferies Healthcare Conference
UTRECHT, The Netherlands and CAMBRIDGE, Mass., June 03, 2022 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced that Bill Lundberg, M.D., President, Chief Executive Officer of Merus, will participate in a fireside chat at the Jefferies Healthcare Conference on Friday, June 10 at 12:45 p.m. ET. The webcast of the fireside chat will be contemporaneously available
